JAMA

JAMA is an international peer-reviewed general medical journal published weekly online and in print, and a member of the @JAMANetwork family of journals.

[JAMA @JAMA_current]

Sleeping fewer than 7 hours is associated with weight gain over time, and sleep deprivation may alter leptin and ghrelin in ways that increase appetite.

🎙️ Listen to Atul Malhotra, MD, from the University of California, San Diego, discuss evidence regarding sleep and obesity with JAMA Deputy Editor Mary McDermott, MD.

https://t.co/wSsLavKEz2

[JAMA @JAMA_current]

💡 JAMA Insights: #SleepHealth and #obesity are linked, with insufficient sleep quantity and poor sleep quality associated with weight gain, less healthy diet, and incident obesity.

https://t.co/i6gIPBiNa1

[JAMA @JAMA_current]

💬 Editorial by Mark Huffman, MD, MPH, Victor Dávila-Román, MD, and Anubha Agarwal, MD: The Global Burden of Disease 2023 estimates for #LDLCholesterol support moving from measurement to implementation through #population policies and #health system strategies.

The World Health Organization’s Global Hearts Initiative, the World Heart Federation’s Cholesterol Roadmap, and the Pan American Health Organization’s HEARTS in the Americas initiative may help expand #cholesterol testing and treatment access.

https://t.co/P2bdRyLbRc

[JAMA @JAMA_current]

Elevated #LDLCholesterol accounted for 3.6 million deaths and 90.7 million disability-adjusted life-years worldwide in 2023, mainly through ischemic #HeartDisease and ischemic #stroke.

🔗 https://t.co/DBmW0aY7t0

[JAMA @JAMA_current]

Although age-standardized #death and #disability-adjusted life-year rates declined since 1990, the total burden increased as #population growth and #aging shifted more of the burden toward middle-sociodemographic countries.

🔗 https://t.co/DBmW0aY7t0

[JAMA @JAMA_current]

📣 JAMA Clinical Guidelines Synopsis: The 2025 #UlcerativeColitis guideline recommends stool testing for C difficile before UC diagnosis, fecal calprotectin for monitoring, and a stepwise approach to 5-ASA, corticosteroids, and advanced therapies. https://t.co/u4hXKUPbse

[JAMA @JAMA_current]

Nearly 90% of US adults report social media use; sharing health information and participating in online communities are common, but 78% distrust health information on these platforms regardless of chronic condition status. https://t.co/aIuIKXeAjh

[JAMA @JAMA_current]

Hearing aids are small electronic devices that fit into the ears and amplify sounds for individuals with hearing loss. It is projected that by 2030, about 35 million adults in the US will have mild hearing loss. Learn more in this Patient Page: https://t.co/HySMORSRzZ

[JAMA @JAMA_current]

Among adults with #CKD due to glomerular diseases, finerenone slowed eGFR decline, reduced albuminuria, and lowered risk of kidney failure, with consistent benefits across disease subtypes and in those using #SGLT2 inhibitors. #ERA26 https://t.co/wj905YItFx

[JAMA @JAMA_current]

💬 Editorial: Despite lower LDL-C treatment targets in the 2026 #Dyslipidemia guideline, most US adults above goal are not on therapy, highlighting gaps in #ASCVD prevention. https://t.co/1R3x50rjjH

[JAMA @JAMA_current]

#MedNews: A new study finds that the first FDA-cleared #Alzheimer disease blood test may yield more false positives than expected in real-world use. https://t.co/NlVSTVFCKy

[JAMA @JAMA_current]

📌 Editor’s Choice from this week's issue of JAMA:

➡️ Low-Dose #Rivaroxaban and CV Events in Advanced #CKD,
➡️ #HearingAids for Adults With Mild to Moderate #HearingLoss,
➡️#Biomarker-Based Eligibility for #LungCancer Screening, and more.

https://t.co/ZcbSdwHmoS

[JAMA @JAMA_current]

💡JAMA Insights: #HearingLoss affects almost 55 million US adults, but traditional #Medicare does not cover hearing aids. OTC hearing aids can now be purchased without professional fitting, expanding access for patients.

https://t.co/bxNsYOygQj

[JAMA @JAMA_current]

Protein-based INTEGRAL-Risk identified 85% of lung cancer cases at 1 year vs 63% by USPSTF 2021, suggesting improved screening efficiency for patients with a smoking history.

https://t.co/NOAQ3MVR0v

[JAMA @JAMA_current]

📊 Research Summary: In advanced #CKD, low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding rates versus placebo.

https://t.co/l1LheI7GhT

[JAMA @JAMA_current]

💬 Editorial: In advanced #CKD, low-dose rivaroxaban did not reduce cardiovascular events and increased major bleeding risk. The TRACK trial highlights the necessity of disease-specific evidence before adopting preventative therapies.

https://t.co/2nIn5CsFdT

[JAMA @JAMA_current]

Among adults with CKD stage 4/5 or on dialysis, low-dose rivaroxaban did not lower cardiovascular risk but did raise major bleeding rates, supporting guideline caution in this group.

https://t.co/j55RoD2Ms1

[JAMA @JAMA_current]

📊 JAMA Research Summary: Among adults with #Stroke from #MDVO, mechanical thrombectomy did not increase the chance of recovery (62% vs 68% with medical care alone) and was associated with higher risk of symptomatic intracranial hemorrhage. https://t.co/uZiSg4yS59

[JAMA @JAMA_current]

Med News: The first clinical guidelines for cardiovascular-kidney-metabolic, or #CKM, syndrome, have arrived. Here’s what they say about diagnosing, staging, and treating the condition. https://t.co/yM7dJHTk5M

[JAMA @JAMA_current]

💬 Perspective: #ArtificialIntelligence may increase efficiency and diagnostic support in medicine, but its value will depend on whether time saved is redirected to face-to-face patient care rather than more screen-based work.

https://t.co/YYV22F34uc